Malaysia is a middle-income country with a population of 27.9 million and a gross domestic product per capita of US $6913(RM23 674) in 2009.1 The number of patients on renal replacement therapy (RRT) increased from 7965 in year 2000 to 23 346 in 2009.2 In 2009, the rate of end-stage renal disease (ESRD) was 837 per million population (pmp) which was comparable to treatment rates in developed nations with higher gross domestic product per capita, such as Australia(850 pmp) and New Zealand(863 pmp).3
In 2009, 92% of the patients on RRT in Malaysia were on dialysis—only 8% received a kidney transplant. This is despite transplantation being available in Malaysia for more than 3 decades. The first living-donor kidney transplant (LKT) was performed in 1975, followed a year later by the first deceased donor kidney transplant (DKT). Over the ensuing years, in comparison with dialysis expansion, the transplant rate has remained low with an average of 60 transplants annually.2 In 2009, the incidence rate of local transplant was only 3 pmp, including both LKT (31%) and DKT (26%). The number of patients benefiting from the local kidney transplant program is therefore small, and an assessment of the cost-effectiveness (CE) of transplantation was important.
The CE of center hemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health (MOH) hospitals4 had previously been evaluated in 2001 but no evaluation of kidney transplantation had been performed. Although studies have established the CE of kidney transplantation in developed countries, such as the United States,5,6 Canada,7 United Kingdom,8 and Netherlands,9 there are limited published economic evaluations from low- and middle-income countries. To our knowledge, fewer than 10 studies on this topic exist outside of high-income countries, and to date, no studies have examined quality of life (QOL) pretransplantation and posttransplantation in a middle-income country. Therefore, we embarked on this study with the aim to evaluate the costs and outcomes of DKT and LKT in adult and pediatric ESRD patients in Malaysia.
MATERIALS AND METHODS
Study Design and Population
The study used both prospective and retrospective data collection for 4 groups of transplant recipients: adult LKT, adult DKT, pediatric LKT, and pediatric DKT. The primary outcomes of interest were costs and utility of transplantation, derived from the results of survival and QOL analysis. Analysis was conducted based on intention-to-treat. The time horizon of the study was the lifetime of the transplant recipient from transplant to death. The perspective of the study was that of the MOH because it is the main provider and fully funds all transplants performed in MOH hospitals. Hence, only health consequences and costs incurred by MOH were included. Transplants performed overseas were not included due to absence of accurate primary data on costing. In addition, since the Declaration of Istanbul, the number of transplants from overseas have declined dramatically from 47.5% in 20092 to 13.8% in 2013.10 Sources of data used in the study are as shown in Table 1.
Inclusion criteria were patients with medical records (≥80% data availability) who received a kidney transplant in Malaysia between 1991 and 2009. All patients transplanted between 2008 and 2009 were included. For patients transplanted in 2009, there was 1-year prospective data collection, and for those transplanted in 2008, there was prospective data for the costs in the second year of transplant and retrospective data for first year costs. To obtain long-term transplant cost data, stratified sampling was performed for those transplanted before 2008. A master list of all local transplant recipients was generated from the Malaysian Dialysis and Transplant Registry (MDTR) database, and patients were stratified by the duration posttransplant, that is, 2 to 5, 5 to 10, and over 10 years posttransplant. Sample size obtained was 30 patients per stratum.
The study was registered and approved by the Medical Research and Ethics Committee under the National Institutes of Health (project ID: NMRR-08-1301-2669).
Graft and patient survival analyses were conducted using data from the MDTR that included all transplant recipients who received grafts from 1991 to 2009. The Kaplan-Meier product-limit survivor function approach was used to estimate mean survival time for the analysis because it best fits the available data and was consistent with previously reported survival estimates.11
Separate graft and survival analyses were performed for adult LKT, adult DKT, pediatric LKT and pediatric DKT. From the mean graft and life survival duration for each type of patient, we derived a mean duration of graft survival, followed by graft failure and survival time on dialysis thereafter until death. Although recipients could possibly receive another organ subsequent to graft failure, this is very rare in Malaysia and was not considered in the study.
QOL and Utility Analysis
The QOL was measured prospectively among adult subjects using the EQ-5D-3L instrument.17 The Malay, Chinese, and English language EQ-5D-3L instruments have been validated for use in a Malaysian population.12 Pretransplant QOL was obtained through a survey of dialysis patients on waiting list for DKT within the electronic Malaysian Organ Sharing System (eMOSS) in 2009. Posttransplant QOL was obtained through surveys of patients transplanted in 2008 and 2009 who completed 4 QOL questionnaires at 1, 3, 6, and 12 months posttransplant.
The utility score with a stable, functioning graft was assumed to be equal to that at 12 months posttransplant. Utility levels after graft failure were assumed to be the same as pretransplant utility while on dialysis. The QOL assessment was not performed for pediatric patients due to lack of an appropriate, validated questionnaire that could be readily converted to QALYs in a Malaysian pediatric population.
Costs considered in this study are direct medical costs incurred by the MOH over the lifetime of transplant patients, as well donors' costs and overhead costs of the transplant program. Patient level costs incurred by transplant recipients and organ donors were estimated by microcosting of resource utilization data extracted via reviews of medical records. Resources estimated through microcosting included hospitalization, medications, laboratory and radiological investigations, procedures, referrals, surgery, transportation and outpatient clinic visits incurred pretransplant, during the transplant admission, posttransplant care and the cost of dialysis from graft failure to death. For donors, the direct medical costs estimated through microcosting included work-up costs, nephrectomy operation and postoperative care.
Overhead costs of the transplant program consisting of hospitals overheads, and program costs of the National Transplant Resource Centre (NTRC) and the eMOSS were apportioned to transplant patients through top-down costing. Because the NTRC and eMOSS cover transplants for all organs, their costs were allocated to kidney transplantation according to the allocation factors (proportion of organs transplanted), and further apportioned to each transplant recipient. The eMOSS costs were allocated equally to all transplant recipients (DKT and LKT) because all patients, irrespective of organ source, are registered into the MOSS system. Conversely, NTRC costs were allocated to DKT recipients only as the NTRC manages the infrastructure for organ procurement from deceased donors (DDs).
Hospital overhead costs included the costs of land and building amortized over 30 years, as well as utilities, maintenance, departmental human resource, and program costs. These costs were then allocated to each patient by top-down costing using allocation factors, based on location of transplant center and home treatment center. Costs upon returning to dialysis until death used previously published data.4 More details on the cost data and data sources are shown in Table 1.
Prices of resources were obtained from both public and private sector sources (see Table 1). Where MOH resource costs were not available, shadow pricing from the private sector was used. All costs were standardized to year 2009 Malaysian Ringgit (RM) and the equivalent costs in 2009 US dollars were obtained using a conversion rate of US $1 = RM3.4245.1
Cost-effectiveness of kidney transplantation was analyzed separately for all 4 groups of recipients and reported as cost per life year (LY). In addition, cost per quality-adjusted LY (QALY) for adult DKT and adult LKT was also calculated. As recommended by Malaysian and international guidelines, costs and outcomes were adjusted to 2009 values at a discount rate of 3% per annum in base case analysis.18,19
Univariate sensitivity analysis was performed to determine the impact of cost variations on the CE of each patient and transplant type. Costs were varied by ±25% from their mean values in the analysis. Lastly, sensitivity analysis was conducted by calculating the CE using undiscounted costs and outcomes and for variables with uncertain values.18-20 These included varying the measures of utility used in the calculation of QALYs, costs of NTRC on the DD kidney transplant program, and hospital overhead costs. Statistical analysis was performed using Stata 11.2 SE statistical software.21
A total of 206 patients were included—118 adults (55 DKT, 63 LKT) and 88 children (49 DKT, 39 LKT). The study sample included all 96 KT recipients who were transplanted in the years 2008 to 2009 and 110 subjects randomly selected from 1991 to 2007 using stratified sampling based on duration posttransplant. The mean age of adult recipients was 33.4 ± 10.3 years and 41.8 ± 8.9 years in LKT and DKT, respectively (Table 2). Among pediatric recipients, mean age was 12.3 ± 3.4 years and 14.0 ± 2.4 years for LKT and DKT, respectively. Fifty-six percent of all recipients were men. The cause of ESRD in 30% of adults and 50% of children was chronic glomerulonephritis. However, the cause of ESRD was unknown in a large percentage due to late presentation. Mean duration of dialysis pretransplant in adults was 2.5 years for LKT, 12.5 years for DKT, whereas it was 2.0 years for LKT, 5.5 years for DKT among pediatric recipients.
Survival and QOL Outcomes
The QOL measured by the EQ-5D-3L was significantly higher for all adult recipients at 1 year posttransplant compared with pretransplant (Table 3). Baseline pretransplant utility was 0.91. At 1 year posttransplant, utility was significantly higher at 0.99 (P = 0.031) for LKT and 1.0 (P = 0.022) for DKT.
Table 4 shows the number of LYs posttransplant. The average discounted LY for adult and pediatric LKT was 13.90 and 14.77, respectively (undiscounted LY, 18.26 and 19.80). In adult and pediatric DKT, the average discounted LY was 11.14 and 10.63, respectively (undiscounted, 13.76 and 12.99, respectively). Based on EQ-5D-3L index utility scores in adults, average discounted QALYs were 13.56 for LKT and 10.83 for DKT (undiscounted, 17.67 and 13.29, respectively).
Cost and Cost Utility
Average undiscounted costs for adult patients in the first year were US $24 452(RM83 735) for LKT and US $42 185 (RM144 475) for DKT including costs from pretransplant work-up, transplant operation, and costs to the end of the first year. Average annual costs declined to US $5247(RM17 970) and US $8427 (RM28 857), respectively, from second year onward (Table 5). In pediatric patients, average costs from first year were US $25 188 (RM86 258) and US $29 005 (RM99 328) for LKT and DKT, respectively. Average annual costs declined in the second year onward to US $7278 (RM24 925) and US $12 291 (RM42 092), respectively. In both adult and pediatric patients, drugs accounted for the major component of costs. Average lifetime discounted costs from pretransplant work-up to death were US $119 702(RM409 921) for adult LKT, US $147 152(RM503 922) for adult DKT, US $154 181(RM530 252) for pediatric LKT and US $159 313(RM545 566) for pediatric DKT (Table 6).
As shown in Table 6, the cost per LY for adult LKT was US $8609(RM29 482) and US $13 209(RM45 234) for adult DKT. For pediatric recipients, the cost per LY was US $10 485(RM35 905) for LKT and US $14 985(RM51 317) for DKT. Cost-utility analysis in adult transplants using the EQ-5D-3L showed the cost per QALY for LKT was US $8826(RM30 224) compared with US $13 592(RM46 547) for DKT.
At zero discount rates, the cost per LY of adult LKT and DKT was US $8287 (RM28 380) and US $12 463 (RM42 680), respectively, as shown in Table 7. For pediatric recipients, the cost per LY of LKT and DKT was US $9955 (RM34 092) and US $13 706 (RM46 956), respectively, as seen in Table 8.
Univariate sensitivity analyses showed that cost per LY was most sensitive to variations in the annual follow-up costs with a functioning graft as shown in Figures 2A to D. These variations were +/-25% of the costs shown in Table 9 Cost per LY ranged from US $7573 (RM25 933) to US $9646 (RM33 031) for adult LKT, US $11 837 (RM45 234) to US $14 580 (RM49 930) for adult DKT, US $9104 (RM31 178)) to US $11 865 (RM40 631) for pediatric LKT, and US $12 428 (RM42 559) to US $17 543 (RM60 075) for pediatric DKT. Detailed data inputs and cost per LY values from univariate sensitivity analysis can be viewed in Table 9. Scenario sensitivity analyses by varying overhead costs of hospitals and the NTRC did not substantially diverge from the cost per LY from base case analysis as seen in Tables 7 and 8.
A review on the global role of kidney transplantation has highlighted that less-developed countries face problems such as inadequate infrastructure, insufficient trained workforce, and lack of a legal framework governing brain death.22 These limitations may be further compounded by patient anxieties regarding successful transplant outcomes, physician bias, incentives favoring dialysis, and geographical remoteness.
In Malaysia, numerous initiatives to support kidney transplantation have been introduced over the last 15 years. These include the establishment of NTRC, tissue and organ procurement teams in major MOH hospitals, MOSS, and a National Transplant Coordinating Committee to coordinate and improve transplant-related activities and requirements. In 2007, the National Organ, Tissue and Cell Transplantation Policy was introduced to provide guiding principles for organ, tissue, and cell transplantation in Malaysia. A specific budget for transplant-related needs has been set aside by the MOH. The MOH collaborates with professional societies and nongovernmental organizations to promote transplantation. Local religious leaders have supported deceased organ donation with a decree issued by the National Fatwa Council in 1970. Despite all the aforementioned initiatives, there has been no evaluation of the transplant program to date.
This study was the first in Malaysia and Southeast Asia to explore the costs and outcomes of kidney transplantation. Our study has found that the average costs ranged from US $8609 (RM29 482) per LY for adult LKT to US $14 985(RM51 317) per LY for pediatric DKT. Average cost per QALY was US $8825(RM30 224) for adult LKT and US $13 509 (RM46 546) for adult DKT. The cost per year of transplantation compares favorably with the annual cost of chronic hemodialysis of US $11 843(RM40 557) and US $11 137(RM38 138) as reported by Hooi et al4 adjusted to 2009.13 However, this is only a preliminary comparison as the study did not set out specifically to do a CE analysis of transplantation compared to dialysis. This study is planned for a later date.
The major component of cost was related to medications. There was a variation in treatment-related costs over different periods. Between 1991 and 1999, the majority of patients were prescribed cyclosporine, prednisolone and azathioprine. After the introduction of tacrolimus and mycophenolate mofetil in Malaysia in 2000, most new patients were on a combination of these two agents with prednisolone. However, the impact of the changing patterns in immunosuppressive regimens on costs and clinical outcomes was not studied separately. The second largest component of costs was for investigations and procedures. These costs were greater for the pediatric group due to the need of general anesthesia for most procedures.
The third most important cost component is total overhead costs which includes costs of land, buildings, utilities, emolument, eMOSS, and NTRC. Because this cost is fixed irrespective of volume of transplant, CE can be improved by increasing the number of transplants.
In this study, the increased QOL of patients posttransplant was notable. There was a relatively high baseline utility value of 0.91 in the pretransplantation cohort which was partly explained by the exclusion of patients aged more than 60 years and those with major comorbidities from the DD transplant waiting list. Furthermore, it has been shown in other studies that Malaysian patients tend to report higher utility values than subjects from other countries.2,12,23 This may be due to our Asian background where acceptance of life events is unusually high, there are cultural taboos in certain ethnic groups about reporting illness and hence, there is a tendency to overrate QOL despite having significant morbidity and complaints. Therefore, QOL assessment is difficult, and the impact of transplant in the Asian patient may appear attenuated. Nonetheless, despite the high baseline utility value in this study, utility values increased significantly to 0.99 and 1.00 at 1 year among adult LKT and DKT patients, respectively. This finding was similar to the data on QOL reported in MDTR 2012 where 90% of transplant patients recorded the maximum QOL score of 10 on the Spitzer's QOL index.2 From our own unpublished data, patients report marked improvement in their QOL posttransplant despite only a 0.08 to 0.09 improvement in utility values.
Currently in Malaysia, cost data are not available from administrative databases. Hence, a major strength of this study was the microcosting approach relying on significant data collection through manual patient chart review and liaison with various administrative bodies for detailed case report form entry to determine resource use (Table 1). Economic valuation of resource use was based on market prices with adjustments for inflation and time preference. The study relied on the MDTR database, a long-term registry which formed the primary source for survival outcome. Our study was comprehensive by including broader program costs such as the national DD organ procurement and allocation systems, that is, NTRC and eMOSS. We also included lifetime costs from time of transplant to death.
Primary limitations of this study are those common to health economic analyses which include extrapolation over patients' lifetimes and necessity to combine various data sources.24 We set out to conduct stratified random sampling to assess resource use of patients transplanted earlier than 2008 but disqualified 31% of the original sample because of incomplete data, leading to resampling. Hence, sampling bias may exist. Second, due to logistics for QOL evaluation in DKT, the pretransplant cohort (patients from DD transplant waiting list) was not the same as the posttransplant cohort.
Costs used were another limitation. Where public sector costing information was not available, shadow pricing from private centers was used. For calculation of costs over lifetime, dialysis costs were adjusted for inflation13 from the previous economic evaluation of dialysis in Malaysia.4 Although it would have been the ideal comparison, the lack of readily available and current dialysis cost data did not permit CE analysis of transplant versus dialysis within the same study. Furthermore cost per QALY cannot be compared because this was not measured in the previous economic evaluation of dialysis.
Another obvious limitation is lack of generalizability to other countries due to differences in study methodology, patient populations, clinical practices and economic settings. However, it is still useful to examine trends for costs between countries. Our study results were similar to other studies showing highest costs of transplant in the first year with a steep decline from second year onward (Table 10). In our study, cost reductions in the second year ranged from 58% to 80%.
This study has demonstrated favorable costs and improved QOL with kidney transplantation and hence justifies all the initiatives to promote transplantation. However, cultural and religious barriers still remain. In addition, health care professionals themselves may represent another significant barrier to organ donation. A recent local study conducted in 2 tertiary hospitals has identified several shortcomings including misunderstanding of the concept of brain stem death, general passivity, and lack of knowledge to initiate the process of organ donation among health care professionals.29
Slow growth in LKT may be due to increased availability of dialysis treatment options in Malaysia. This has reduced the perceived need for relatives to donate kidneys. As opposed to dialysis which is now provided mainly by the private sector2, there are no financial incentives for health care professionals to promote kidney transplantation. To increase the living donor pool, Malaysia embarked on ABO-incompatible kidney transplantation in 2011. Increasing preemptive transplants would also improve CE of living donor transplantation because of improved transplant outcomes.30 However, this is often not feasible due to delayed referral of patients to nephrologists. Therefore, it is clear that much more effort is required to educate both the public as well as health care professionals regarding chronic kidney disease and transplant options.
Finally, this study will provide an information base for further research into the health economics of RRT in Malaysia.
Kidney transplantation in Malaysia is cost-favorable and results in better QOL for ESRD patients. This study has provided evidence for local health authorities to continue to support the existing national kidney transplant program. Our study also forms the basis for further research to establish the CE of kidney transplantation against alternative forms of RRT.
This study would not have been possible without the support and collaboration of many individuals and professional bodies. The authors would in particular like to thank: all nephrologists and allied healthcare professionals who helped in data collection, especially members of the Collaborative Kidney Transplant Economic Study Group: Hooi LS, Liu WJ (Hospital Sultanah Aminah Johor Bahru), Susan Pee (Hospital Sultan Ismail, Johor Baru), Ong LM, Rozina Ghazalli, Lynster Liaw, Liew YF (Hospital Pulau Pinang), Zawawi Nordin (Hospital Kuala Terengganu), Clare Tan, Laura Ngu (General Hospital Kuching), Sukeri Mohamad, Zuad Firdaus Rapiah (Hospital Raja Perempuan Zainab II), Ching CH (Hospital Sultanah Bahiyah Alor Setar), Thong KM, Lim YN, Masaamah Masood (Hospital Kuala Lumpur), Lee ML (Hospital Tuanku Jaafar), Chitra Ramasamy (Hospital Selayang), The National Transplant Resource Centre, Malaysia, The Malaysian Dialysis and Transplant Registry, S. Manjulaa Devi and Nurul Hizwani Azahar, MOH renal pharmacists, Yee Siau Lin of Azmi Burhani Consulting for assistance with statistical analysis, The National Clinical Research Centre, Malaysia, The Malaysian Society of Nephrology, Post Graduate Renal Society Malaysia and National Institutes of Health for financial support, The EuroQol Group for permission to use the EQ-5D-3L instrument, Sarah White and Steve Chadban, University of Sydney, Australia for reviewing the manuscript and valuable comments. Finally, the authors thank the Director-General of Health in Malaysia for permission to publish this paper.
1. Ministry of Finance Malaysia Economic Report 2010–2011
. Kuala Lumpur: National Printing Press Ltd.
2. Lim YN, Goh BL, Ong LM, editors. Twentieth Report of the Malaysian Dialysis and Transplant Registry 2012
. Kuala Lumpur: 2013.
3. U.S.Renal Data System, USRDS 2011. Annual Data Report : Atlas of Chronic Kidney Disease and End-Stage Kidney Disease in the United States, National Institute of Diabetes and Digestive and Kidney Diseases
. Bethesda, MD: 2011.
4. Hooi LS, Lim TO, Goh A, et al Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health Hospitals, Malaysia. Nephrology
5. Klarman HE, Francis JO, Rosenthal GD. Cost effectiveness analysis applied to the treatment of chronic renal disease. Med Care
6. Garnier TI, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care
7. Laupacis A, Keown P, Pus N, et al A study of the quality of life and cost-utility of renal transplantation. Kidney Int
8. Ludbrook A. A cost-effectiveness analysis of the treatment of chronic renal failure. Appl Econ
9. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy
10. Goh BL, Ong LM, Lim YN, editors. Twentyfirst Report of the Malaysian Dialysis and Transplant Registry 2013
. Kuala Lumpur: 2014.
11. Lim YN, Goh BL, Ong LM, editors. Eighteenth Report of the Malaysian Dialysis and Transplant Registry 2010
. Kuala Lumpur: 2011.
12. Faridah A, Goh A, Soraya A. Estimating an EQ-5D value set for Malaysia using time trade-off and visual analogue scale methods. Value Health
. 2012;15(1 Suppl):S85–S90.
14. Valuation and Property Services Department. Key Data 2012. Available at http://napic.jpph.gov.my/epsKeyStatistics/keyst/streamFile.dl?itemId=1542&org.jboss.portletbridge.NAMESPACE=jbpns_2feps_2fdefault_2fEpsKeyStatisticsPortletWindowsnpbj.
15. UBM Medica. MIMS Malaysia 127th Edition
16. Malaysian Medical Association. Schedule of Fees 5th Edition
17. The EuroQOL Group. EuroQOL—a new facility for the measurement of health-related quality of life. Health Policy
18. Pharmaceutical Services Division, MOH. Pharmacoeconomic Guideline for Malaysia
19. Gold MR, Siegel JE, Russell LD, Weinstein MC, editors. Cost-Effectiveness in Health and Medicine
. Oxford: Oxford University Press; 1996.
20. Drummond MF, O'Brien BJ, Stoddart GL, et al Methods for the Economic Evaluation of Health Care Programs
. 2nd ed. Oxford: Oxford University Press; 1996.
21. StataCorp. Stata: Release 11: Survival Analysis and Epidemiological Tables. Statistical Software
. College Station, TX: StataCorp LP; 2009.
22. Garcia GG, Harden P, Chapman J; for the World Kidney Day Steering Committee 2012. The Global role of kidney transplantation. J Nephropathol
23. Azmi S, Goh A, Fong A, et al Quality of Life among patients with acute coronary syndrome in Malaysia. Value in Health Regional Issues
24. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care
25. Kontodimopoulos N, Niakas D. An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. Health Policy
26. Howard K, Salkeld G, White S, et al The cost-effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology
27. Yen EF, Hardinger K, Brennan DC, et al Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of kidney transplant. Am J Transplant
28. Nakajima I, Akamatsu M, Tojimbara T, et al Economic study of renal transplantation: a single-centre analysis in Japan. Transplant Proc
29. Abidin ZLZ, Ming WT, Loch A, et al Are health professionals responsible for the shortage of organs from deceased donors in Malaysia? Transpl Int
30. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor-kidney analysis. Transplantation